- Home
- APPS vs GTHX Comparison
APPS vs GTHX Comparison
Compare APPS & GTHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- GTHX
- Stock Information
- Founded
- APPS N/A
- GTHX 2008
- Country
- APPS United States
- GTHX United States
- Employees
- APPS N/A
- GTHX N/A
- Industry
- APPS Multi-Sector Companies
- GTHX Biotechnology: Pharmaceutical Preparations
- Sector
- APPS Miscellaneous
- GTHX Health Care
- Exchange
- APPS Nasdaq
- GTHX Nasdaq
- Market Cap
- APPS 428.8M
- GTHX 376.2M
- IPO Year
- APPS N/A
- GTHX 2017
- Fundamental
- Price
- APPS $2.92
- GTHX $7.15
- Analyst Decision
- APPS Hold
- GTHX Buy
- Analyst Count
- APPS 2
- GTHX 4
- Target Price
- APPS $5.25
- GTHX $3.50
- AVG Volume (30 Days)
- APPS 3.4M
- GTHX 1.6M
- Earning Date
- APPS 11-06-2024
- GTHX 10-30-2024
- Dividend Yield
- APPS N/A
- GTHX N/A
- EPS Growth
- APPS N/A
- GTHX N/A
- EPS
- APPS N/A
- GTHX N/A
- Revenue
- APPS $516,105,000.00
- GTHX $58,195,000.00
- Revenue This Year
- APPS $2.50
- GTHX N/A
- Revenue Next Year
- APPS $9.57
- GTHX $28.49
- P/E Ratio
- APPS N/A
- GTHX N/A
- Revenue Growth
- APPS N/A
- GTHX N/A
- 52 Week Low
- APPS $1.39
- GTHX $1.08
- 52 Week High
- APPS $7.33
- GTHX $7.19
- Technical
- Relative Strength Index (RSI)
- APPS 48.98
- GTHX 83.27
- Support Level
- APPS $2.57
- GTHX $7.10
- Resistance Level
- APPS $2.99
- GTHX $7.15
- Average True Range (ATR)
- APPS 0.23
- GTHX 0.02
- MACD
- APPS -0.09
- GTHX -0.12
- Stochastic Oscillator
- APPS 33.47
- GTHX 50.00
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About GTHX G1 Therapeutics Inc.
G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.